FDA issues warning on Tussionex use
The Food & Drug Administration has issued a warning to practitioners on the appropriate use of Tussionex Pennkinetic Extended-Release Suspension, containing hydrocodone. Reports received by the agency have revealed that physicians and other healthcare professionals are inappropriately prescribing the medication, leading to serious adverse events in some cases, including death. The FDA warning reminds practitioners that the cough suppressant is not to be administered any more frequently than every 12 hours and is contraindicated in children less than six years old. In addition, prescribers should consult the prescribing information to determine an accurate dose, and should instruct patients not to take the cough medicine any more frequently than every 12 hours, using a medicine syringe for measuring the dose rather than a household teaspoon or tablespoon. According to the FDA, the alert does not impact the short-acting cough products containing hydrocodone that can be given every four to six hours; however, the agency is currently reviewing safety information on these other products and will provide updates as new information becomes available. Tussionex Pennkinetic is manufactured by UCB Inc.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.